Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 2, 2013, Pages 264-270

  Perera, Vidya ^a,b   Gross, Annette S ^a,c   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

^c GLAXOSMITHKLINE   (Australia)

Author keywords

caffeine; CYP1A2 activity; diurnal variation; ethnicity; South Asian

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; PARAXANTHINE;

ADULT; ARTICLE; ASIAN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; NORMAL HUMAN; PHENOTYPIC VARIATION; PROSPECTIVE STUDY; SALIVA ANALYSIS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CAFFEINE; CIRCADIAN RHYTHM; CYTOCHROME P-450 CYP1A2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; SALIVA; THEOPHYLLINE; YOUNG ADULT;

EID: 84871721520     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01594.x     Document Type: Article

References (28)

1. Ohdo S,. Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet 2007; 22: 3-14.
2. Ohdo S,. Biological clock and chronopharmacology. Nihon Shinkei Seishin Yakurigaku Zasshi 2007; 27: 95-102.
3. Bruguerolle B,. Chronopharmacokinetics. Current status. Clin Pharmacokinet 1998; 35: 83-94.
4. Lemmer B,. Chronopharmacology-importance of the biological clock in drug treatment. Med Monatsschr Pharm 2009; 32: 419-425.
5. Kolawole JA, et al,. Chronopharmacokinetics of acetaminophen in healthy human volunteers. Eur J Drug Met Pharmacokinet 2002; 27: 199-202.
6. Lemmer B,. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol 1999; 51: 887-890.
7. Lemmer B, Bruguerolle B,. Chronopharmacokinetics. Are they clinically relevant? Clin Pharmacokinet 1994; 26: 419-427.
8. Baraldo M,. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008; 4: 175-192.
9. Perera V, et al,. Measurement of CYP1A2 Activity: a focus on caffeine as a probe. Curr Drug Metab 2012; 13: 667-678.
10. Bertilsson L, et al,. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
11. Shirley KL, et al,. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 2003; 28: 961-966.
12. Rasmussen BB, Brosen K,. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br J Clin Pharmacol 1997; 43: 253-258.
13. Chauchan BL, et al,. Diurnal variation in the pharmacokinetics of intravenous theophylline and etophylline in healthy subjects. Eur J Clin Pharmacol 1986; 30: 635-636.
14. Rodgers A, et al,. Effects of time of dosing and age on intravenous aminophylline pharmacokinetics. Br J Clin Pharmacol 1987; 23: 344-347.
15. Starek A,. Circadian variations of phenacetin metabolism in rats in vivo and in vitro. Pol J Pharmacol Pharm 1992; 44: 663-670.
16. Perera V, et al,. Pharmacokinetics of caffeine in plasma and saliva and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol 2011; 63: 1161-1168.
17. Simon T, et al,. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol 2001; 52: 601-604.
18. Butler MA, et al,. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
19. Peterson S, et al,. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem Toxicol 2006; 44: 1474-1484.
20. Peterson S, et al,. CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidem Biomar 2009; 18: 3118-3125.
21. Klein K, et al,. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 2010; 1: 1-20.
22. Dobrinas M, et al,. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90: 117-125.
23. Perera V, et al,. Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin Pharmacol Ther 2012; 2012 Sep 5. doi: 10.1038/clpt.2012.139.
24. Ghotbi R, et al,. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63: 537-546.
25. Perera V, et al,. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed Chromatogr 2010; 24: 1136-1144.
26. Lampe JW, et al,. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000; 21: 1157-1162.
27. Kashuba AD, et al,. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998; 63: 540-551.
28. Gachon F, et al,. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab 2006; 4: 25-36.